Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There are various regimens for thromboprophylaxis after hip replacement. Low-molecular-weight heparins such as enoxaparin predominantly inhibit factor Xa but also inhibit thrombin to some degree. Orally active, specific factor Xa inhibitors such as apixaban may provide effective thromboprophylaxis with a lower risk of bleeding and improved ease of use. METHODS: In this double-blind, double-dummy study, we randomly assigned 5407 patients undergoing total hip replacement to receive apixaban at a dose of 2.5 mg orally twice daily or enoxaparin at a dose of 40 mg subcutaneously every 24 hours. Apixaban therapy was initiated 12 to 24 hours after closure of the surgical wound; enoxaparin therapy was initiated 12 hours before surgery. Prophylaxis was continued for 35 days after surgery, followed by bilateral venographic studies. The primary efficacy outcome was the composite of asymptomatic or symptomatic deep-vein thrombosis, nonfatal pulmonary embolism, or death from any cause during the treatment period. Patients were followed for an additional 60 days after the last intended dose of study medication. RESULTS: A total of 1949 patients in the apixaban group (72.0%) and 1917 patients in the enoxaparin group (71.0%) could be evaluated for the primary efficacy analysis. The primary efficacy outcome occurred in 27 patients in the apixaban group (1.4%) and in 74 patients in the enoxaparin group (3.9%) (relative risk with apixaban, 0.36; 95% confidence interval [CI], 0.22 to 0.54; P<0.001 for both noninferiority and superiority; absolute risk reduction, 2.5 percentage points; 95% CI, 1.5 to 3.5). The composite outcome of major and clinically relevant nonmajor bleeding occurred in 129 of 2673 patients assigned to apixaban (4.8%) and 134 of 2659 assigned to enoxaparin (5.0%) (absolute difference in risk, -0.2 percentage points; 95% CI, -1.4 to 1.0). CONCLUSIONS: Among patients undergoing hip replacement, thromboprophylaxis with apixaban, as compared with enoxaparin, was associated with lower rates of venous thromboembolism, without increased bleeding. (Funded by Bristol-Myers Squibb and Pfizer; ClinicalTrials.gov number, NCT00423319.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The WARFASA 309 and ASPIRE 318 trials compared aspirin, 100 mg daily, with placebo for secondary prevention of recurrent VTE for patients with an initial unprovoked event, and the pooled results of the 2 trials showed a decrease in recurrent VTE, as well as major vascular events, without an increased risk for clinically relevant bleeding. 309,315”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [318]
In the citing paper
“The investigation into the use of the lower doses of these 2 anticoagulants for secondary prevention was prompted by the desire to reduce the risk of bleeding, as well as the documented efficacy of the lower doses to prevent VTE after elective hip or knee arthroplasty. 317-321”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [318]
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Self-citationSCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Prevention of Venous Thromboembolism
Geerts, W. H., Heit, J. A., Clagett, G. P., Pineo, G. F., Colwell, C. W., Anderson, F. A., & Wheeler, H. B. (2001) · Chest · doi:10.1378/chest.119.1_suppl.132s · Cited by 4,373
Self-citationPrevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
Self-citationSCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Self-citationDabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Self-citationRivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800374 · Cited by 1,433
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
Lassen, M. R., Ageno, W., Borris, L. C., Lieberman, J. R., Rosencher, N., Bandel, T. J., Misselwitz, F., & Turpie, A. G. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa076016 · Cited by 1,295
Self-citation
Cited by
Items 201–300 of 780
Prevention of VTE in patients having major orthopedic surgery
Francis, C. W. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-0889-9 · Cited by 34
“5 mg twice daily starting 12–24 h after surgery [27–30].”
BackgroundCocero, N., Basso, M., Grosso, S., & Carossa, S. (2018) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2018.09.024 · Cited by 31
“The most commonly used DOACs are dabigatran, a direct thrombin inhibitor that has an 80 to 85% renal excretion rate and a half-life of 12 to 17 hours,(15,16) and the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban, which have renal excretion rates of 25 to 35% and half-lives of 5 to 9, 8 to 15, and 10 to 14 h…”
BackgroundNew anticoagulants: A concise review
Kreuziger, L. B., Morton, C. T., & Dries, D. J. (2012) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e318265cf9e · Cited by 31
Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence
Bracey, A., Shatila, W., & Wilson, J. M. (2018) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944718801554 · Cited by 31
Cornell, R. F., Goldhaber, S. Z., Engelhardt, B. G., Moslehi, J. J., Jagasia, M., Patton, D., Harrell, S. L., Hall, R., Wyatt, H., & Piazza, G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00045 · Cited by 30
Assessment of Patient Adherence to Direct Oral Anticoagulant vs Warfarin Therapy
Patel, S. I., Cherington, C. C., Scherber, R. M., Barr, K., McLemore, R. Y., Morisky, D. E., Cha, S., Mookadam, F., & Shamoun, F. E. (2017) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2017.002 · Cited by 31
Cove, C. L., & Hylek, E. M. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000136 · Cited by 32
Amarase, C., Tanavalee, A., Larbpaiboonpong, V., Lee, M. C., Crawford, R., Matsubara, M., Zhou, Y., Asia-Pacific (AP) Region Venous Thromboembolism (VTE) Consensus Group, Unnanuntana, A., Tan, A., et al. (2021) · Knee Surgery and Related Research · doi:10.1186/s43019-021-00101-7 · Cited by 31
Prevention of early complications following total hip replacement
Fontalis, A., Berry, D. J., Shimmin, A., Slullitel, P. A., Buttaro, M. A., Cao, L., Malchau, H., & Haddad, F. S. (2021) · SICOT-J · doi:10.1051/sicotj/2021060 · Cited by 33
“5 mg orally twice daily for 35 days) have also been recommended for VTE prevention for low-and high-risk patients [35, 36].”
BackgroundKinov, P. S., Tanchev, P. P., Ellis, M. H., & Volpin, G. (2013) · International Orthopaedics · doi:10.1007/s00264-013-2134-8 · Cited by 33
“ADVANCE - 3 compared apixaban to enoxaparin (30 mg once daily) in THA and in this study apixaban demonstrated superiority compared enoxaparin, and the incidence of bleeding was the same for both medications [51].”
BackgroundNovel oral anticoagulants: What dermatologists need to know
Plovanich, M., & Mostaghimi, A. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.11.013 · Cited by 30
Practical aspects of the oral new anticoagulants
DeLoughery, T. G. (2011) · American Journal of Hematology · doi:10.1002/ajh.22021 · Cited by 29
“4 [16] 3,057 Enoxaparin 40 mg/day 10–14 15 24 0.”
BackgroundThe new oral anticoagulants: Reasonable alternatives to warfarin
Roca, B., & Roca, M. (2015) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.82a.14052 · Cited by 28
Landge, S. B., Jadhav, S. A., Dahale, S. B., Solanki, P. V., Bembalkar, S. R., & Mathad, V. T. (2015) · American Journal of Analytical Chemistry · doi:10.4236/ajac.2015.66052 · Cited by 28
““Eliquis” is also used after hip or knee replacement surgery to prevent a type of blood clot called deep vein thrombosis (DVT), which can lead to blood clots in the lungs (pulmonary embolism) [1]-[6].”
MethodTreatment with novel oral anticoagulants: indications, efficacy and risks
Ghanny, S., & Crowther, M. A. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328363c170 · Cited by 32
“Concomitant use of strong inhibitors of CYP3A4 and p-GP is not recommended in order to avoid increased serum concentrations [7].”
BackgroundAšić, A., Marjanović, D., Mirat, J., & Primorac, D. (2018) · Personalized Medicine · doi:10.2217/pme-2017-0092 · Cited by 34
Anticoagulation and Spine Surgery
Porto, G. B. F., Wessell, J. E., Alvarado, A. M., Arnold, P. M., & Buchholz, A. L. (2020) · Global Spine Journal · doi:10.1177/2192568219852051 · Cited by 28
“Lassen et al10 in a prospective, randomized, double-blind study assessed 5407 patients undergoing hip replacement for efficacy in thromboembolic prevention and safety profile.”
BackgroundPerka, C. (2011) · Thrombosis Journal · doi:10.1186/1477-9560-9-17 · Cited by 29
“Both trials demonstrated that apixaban was more effective than the European enoxaparin regimen for the primary efficacy outcome and there was no significant difference in the rate of major or clinically relevant bleeding [25,26].”
BackgroundMethodResultCurrent State of Knowledge on Oral Anticoagulant Reversal Using Procoagulant Factors
Nitzki‐George, D., Wozniak, I., & Caprini, J. A. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r724 · Cited by 27
Agarwal, A. R., Das, A., Harris, A. B., Campbell, J. C., Golladay, G. J., & Thakkar, S. C. (2023) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-22-00708 · Cited by 27
Gómez‐Outes, A., Suárez-Gea, Lecumberri, R., Terleira‐Fernández, A. I., Vargas, E., & Rocha (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s35843 · Cited by 28
“69 Apixaban is currently authorized in the European Union and other regions for VTE prophylaxis after total hip replacement or total knee arthroplasty on the basis of the ADVANCE1-3 studies, 70–72 as well as for stroke prevention in atrial fibrillation based on the ARISTOTLE study.”
Llau, J. V., Ferrandis, R., Castillo, J., de Andrés, J., Gomar, C. G., Gómez‐Luque, A., Hidalgo, F., & Torres, L. M. (2012) · Revista Española de Anestesiología y Reanimación · doi:10.1016/j.redar.2012.01.007 · Cited by 32
Fifty years of research on antithrombotic therapy: Achievements and disappointments
Hirsh, J., Eikelboom, J. W., & Chan, N. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.10.023 · Cited by 29
Nederpelt, C. J., Breen, K., Hechi, M. W. E., Krijnen, P., Huisman, M. V., Schipper, I. B., Kaafarani, H. M. A., & Rosenthal, M. D. (2020) · Journal of Surgical Research · doi:10.1016/j.jss.2020.10.009 · Cited by 27
Mandt, S. R., Thadathil, N., Klem, C., Russ, C., McNamee, P. L., Stigge, K., & Cheng, D. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00664-2 · Cited by 28
Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting
Dincq, A.-S., Lessire, S., Douxfils, J., Dogné, J., Gourdin, M. J., & Mullier, F. (2014) · BioMed Research International · doi:10.1155/2014/385014 · Cited by 27
“…prevention of thromboembolic events in nonvalvular atrial fibrillation (NVAF), for thromboprophylaxis of venous thromboembolism (VTE) including deep venous thromboembolism (DVT) and pulmonary embolism (PE) after hip and knee arthroplasty, and for the treatment and secondary prophylaxis of VTE.”
BackgroundEriksson, B. I., Dahl, O. E., Rosencher, N., Clemens, A., Hantel, S., Feuring, M., Kreuzer, J., Huo, M. H., & Friedman, R. J. (2015) · Thrombosis Journal · doi:10.1186/s12959-015-0067-8 · Cited by 26
“7 %) observed in studies with the oral FXa inhibitors (apixaban and rivaroxaban) versus enoxaparin in patients undergoing hip arthroplasty and receiving prophylaxis for an equivalent extended duration [10, 11].”
Thromboprophylaxis for orthopedic surgery; An updated meta-analysis
Haykal, T., Adam, S. S., Bala, A., Zayed, Y., Deliwala, S. S., Kerbage, J., Ponnapalli, A., Malladi, S., Samji, V., & Ortel, T. L. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.12.007 · Cited by 30
Shargall, Y., Wiercioch, W., Brunelli, A., Murthy, S. C., Hofstetter, W. L., Lin, J., Li, H., Linkins, L., Crowther, M., Davis, R., et al. (2022) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezac488 · Cited by 26
Hanna, M. S., Mohan, P., Knabb, R. M., Gupta, E., Frost, C. E., & Lawrence, J. H. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12567 · Cited by 28
Ageno, W., Spyropoulos, A. C., & Turpie, A. G. G. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-11-0787 · Cited by 28
“5 mg bid showed superior efficacy to enoxaparin 40 mg od (34, 35).”
BackgroundThe new oral anticoagulants in atrial fibrillation: Once daily or twice daily?
Renda, G., & Caterina, R. D. (2013) · Vascular Pharmacology · doi:10.1016/j.vph.2013.07.003 · Cited by 28
“5 mg twice daily appeared similar to LMWH in terms of efficacy, and showed a comparable low risk for major bleeding: among patients undergoing total hip or knee replacement, thromboprophylaxis with apixaban was associated with lower rates of venous thromboembolism without increased bleeding compared with enoxaparin [4…”
BackgroundThe new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature
Tahir, F., Riaz, H., Riaz, T., Badshah, M. B., Riaz, I. B., Hamza, A., & Mohiuddin, H. (2013) · Thrombosis Journal · doi:10.1186/1477-9560-11-18 · Cited by 30
“The Apixaban Dosed Orally Versus Anticoagulation with Injectable Enoxaparin to Prevent Venous Thromboembolism 3 (ADVANCE-3) trial [11] compared 5407 patients undergoing hip arthroplasty to receive either 2.”
American College of Foot and Ankle Surgeons® Clinical Consensus Statement: Perioperative Management
Meyr, A. J., Mirmiran, R., Naldo, J., Sachs, B. D., & Shibuya, N. (2017) · The Journal of Foot & Ankle Surgery · doi:10.1053/j.jfas.2016.10.016 · Cited by 27
Kalathottukaren, M. T., Haynes, C. A., & Kizhakkedathu, J. N. (2017) · Drug Delivery and Translational Research · doi:10.1007/s13346-017-0413-4 · Cited by 26
Cimminiello, C., Prandoni, P., Agnelli, G., Minno, G. D., Friz, H. P., Scaglione, F., Boracchi, P., Marano, G., & Harenberg, J. (2017) · Internal and Emergency Medicine · doi:10.1007/s11739-017-1714-9 · Cited by 28
Thiengwittayaporn, S., Budhiparama, N. C., Tanavalee, C., Tantavisut, S., Sorial, R. M., Cao, L., Kim, K., The Asia-Pacific (AP) Region Venous Thromboembolism (VTE) Consensus Group, Unnanuntana, A., Tan, A., et al. (2021) · Knee Surgery and Related Research · doi:10.1186/s43019-021-00100-8 · Cited by 27
“Two RCTs using apixaban showed its superior efficacy compared to enoxaparin [15, 16].”
BackgroundWang, M., Xie, J., Zheng, H., Wang, S., Zhou, R., Li, W., Xue, E. C., Wang, X., Jiang, J., Wu, T., et al. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15005 · Cited by 25
Weitz, J. I., Kithcart, A. P., O’Brien, M. P., Levy, O. A., Marin, E. P., Onisko, M., Mohammadi, K. A., Li, D., Meagher, K. A., Chang, H. H., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02097-5 · Cited by 25
Self-citationSchulman, S., & Majeed, A. (2011) · Drug Safety · doi:10.2165/11587290-000000000-00000 · Cited by 29
“A second orally available anti-Xa inhibitor, apixaban, has also completed its phase III programme (the ADVANCE [Apixaban Dosed Orally Versus Anticoagulation with Injectable Enoxaparin to Prevent Venous Thromboembolism]) in orthopaedic surgery with favourable results compared with enoxaparin, but it has not been approv…”
BackgroundNew Trends in Anticoagulation Therapy
SMITH, M. H. D., Wakam, G. K., Wakefield, T. W., & Obi, A. T. (2018) · Surgical Clinics of North America · doi:10.1016/j.suc.2017.11.003 · Cited by 26
“(14) In the ADVANCE-3(15) and RECORD-1(16) trials, extended duration apixaban and rivaroxaban were both found to be superior to extended duration LMWH for VTE risk reduction amongst THA patients, with a similar safety profile.”
BackgroundCoulis, A. A., & Mackey, W. C. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.10.009 · Cited by 27
Overview of Venous Thrombosis in Inflammatory Bowel Disease
Pürnak, T., & Yüksel, O. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000274 · Cited by 28
Transitions of care in anticoagulated patients
Michota, F. A. (2013) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s44068 · Cited by 29
Anticoagulant therapy: basic principles, classic approaches and recent developments
Sinauridze, E. I., Panteleev, M. A., & Атауллаханов, Ф. И. (2012) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e328355c9cb · Cited by 29
Changing Practice of Anticoagulation: Will Target-Specific Anticoagulants Replace Warfarin?
Arepally, G. M., & Ortel, T. L. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024633 · Cited by 27
Emerging options in the treatment of deep vein thrombosis and pulmonary embolism
Brenner, B., & Hoffman, R. (2011) · Blood Reviews · doi:10.1016/j.blre.2011.04.003 · Cited by 27
“4–1).(38) The conclusion from this study is that thromboprophylaxis with apixaban as compared to enoxaparin among patients undergoing hip replacement was associated with a lower rate of VTE without increased bleeding.”
ResultPharmacology and Laboratory Testing of the Oral Xa Inhibitors
Samama, M. M., Meddahi, S., & Samama, C. M. (2014) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2014.06.009 · Cited by 26
Messerschmidt, C. A., & Friedman, R. J. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303400 · Cited by 27
Lee, Y., Chung, C. Y., Koo, K., Lee, K. M., Ji, H.-M., & Park, M. S. (2012) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.j.01033 · Cited by 25
Liu, Z., Han, N., Xu, H., Fu, Z.-G., Zhang, D., Wang, T., & Jiang, B. (2016) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-016-0917-y · Cited by 26
“Thrombocytopenia was defined as either a reduction in platelet concentration from >150 × 10(19)/L (preoperative) to <100 × 10(19)/L (postoperative), or a >50 % decrease during postoperative period from a preoperative concentration of <150 × 10(19)/L [21].”
BackgroundLusk, K. A., Snoga, J. L., Benitez, R. M., & Sarbacker, G. B. (2017) · Journal of Pharmacy Practice · doi:10.1177/0897190017707126 · Cited by 26
“6% and a minor bleeding risk of up to 14% per year.(1-20) Dabigatran is indicated in treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE), stroke prevention in nonvalvular atrial fibrillation, and prophylaxis of DVT and PE following hip replacement surgery.”
BackgroundAhmed, A. B., Kozek‐Langenecker, S. A., Mullier, F., Pavord, S. R., & Hermans, C. R. J. R. (2017) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000000725 · Cited by 28
Sun, G., Wu, J., Wang, Q., Liang, Q., Jia, J., Cheng, K., Sun, G., & Wang, Z. (2018) · The Journal of Arthroplasty · doi:10.1016/j.arth.2018.11.029 · Cited by 27
Revankar, N., Patterson, J., Kadambi, A., Raymond, V., & BSc, W. E.-H. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.07.2686 · Cited by 24
A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough?
Güler, E., Güler, G. B., Demır, G. G., & Hatipoğlu, S. (2015) · The Anatolian Journal of Cardiology · doi:10.5152/anatoljcardiol.2015.6532 · Cited by 26
Huo, M. (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-10-0653 · Cited by 25
Karimi, K., & Rahsepar, M. (2022) · ACS Omega · doi:10.1021/acsomega.1c05495 · Cited by 23
Marx, S., Dahl, O. E., Marder, V. J., Schulze, A., Wehling, M., Weiß, C., & Harenberg, J. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-07-0482 · Cited by 25
A new paradigm shift in antithrombotic therapy
Pudusseri, A., Shameem, R., & Spyropoulos, A. C. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00133 · Cited by 25
Prevention of Venous Thromboembolism in Total Knee and Hip Replacement
Warwick, D. J. (2012) · Circulation · doi:10.1161/circulationaha.111.055731 · Cited by 24
Apixaban: First Global Approval
Watson, J., Whiteside, G., & Perry, C. (2011) · Drugs · doi:10.2165/11596820-000000000-00000 · Cited by 24
Glickman, A., Brennecke, A., Tayebnejad, A., Matsuo, K., Guntupalli, S. R., & Sheeder, J. L. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.07.096 · Cited by 23
The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects
Frost, C. E., Song, Y. J., Yu, Z., Wang, J. J. J., Lee, L., Schuster, A. E., Pollack, A., & LaCreta, F. P. (2017) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s115687 · Cited by 27
How to prevent, treat, and overcome current clinical challenges of VTE
van Es, J., Eerenberg, E. S., Kamphuisen, P. W., & Buller, H. R. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04334.x · Cited by 24
Kolibaba, K. S., Sterchele, J. A., Joshi, A. D., Forsyth, M., Alwon, E., Beygi, H., & Kennealey, G. T. (2013) · Therapeutic Advances in Hematology · doi:10.1177/2040620713478629 · Cited by 23
Yi, Y.-H., Gong, S., Gong, T.-L., Zhou, L., Hu, C., & Xu, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.775126 · Cited by 23
“Finally, 25 RCTs published up toMay 20, 2021, were included in the network meta-analysis (Eriksson et al., 2008; Kakkar et al., 2008; Lassen et al., 2008; Turpie et al., 2009; Lassen et al., 2007; Lassen et al., 2009; Lassen et al., 2010; Lassen et al., 2010; Eriksson et al., 2007; Eriksson et al., 2011; Eriksson et a…”
BackgroundInfluentialShargall, Y., Wiercioch, W., Brunelli, A., Murthy, S. C., Hofstetter, W. L., Lin, J., Li, H., Linkins, L., Crowther, M., Davis, R., et al. (2022) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2022.05.041 · Cited by 22
Lalmohamed, A., Vestergaard, P., Javaid, M. K., de Boer, A., Leufkens, H. G. M., van Staa, T. P., & de Vries, F. (2013) · The American Journal of Gastroenterology · doi:10.1038/ajg.2013.108 · Cited by 25
Nuevos anticoagulantes orales y su papel en la práctica clínica
Mateo, J. (2013) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(13)70057-8 · Cited by 58
Russell, R. D., Hotchkiss, W. R., Knight, J. R., & Huo, M. H. (2013) · Thrombosis · doi:10.1155/2013/762310 · Cited by 25
“The results for apixaban and dabigatran have demonstrated similar efficacy and safety profiles when compared to enoxaparin, and these drugs have been approved in Canada and countries in Europe [12–17].”
BackgroundNovel oral anticoagulants for thromboprophylaxis after orthopaedic surgery
Quinlan, D. J., & Eriksson, B. I. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.07.003 · Cited by 27
Apixaban and Rivaroxaban Safety After Hip and Knee Arthroplasty: A Meta-Analysis
Alves, C., Marques, F. B., & Macedo, A. F. (2011) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248411427402 · Cited by 28
“Apixaban was proven to be at least as effective as enoxaparin for thromboprophylaxis after total knee or hip arthroplasty.(12,21,22) Although in ADVANCE 1 study apixaban was not shown to be superior to enoxaparin (North American regimen) after knee arthroplasty, it was associated with a lower bleeding risk.”
BackgroundResultInfluentialQuintero, J. I., Cárdenas, L., Navas, M., Bautista, M., Bonilla, G. A., & Llinás, A. (2016) · The Journal of Arthroplasty · doi:10.1016/j.arth.2016.03.025 · Cited by 23
Milinis, K., Shalhoub, J., Coupland, A., Salciccioli, J. D., Thapar, A., & Davies, A. H. (2018) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2018.05.020 · Cited by 22
Direct-Acting Oral Anticoagulants in Critically Ill Patients
Rali, P. M., Gangemi, A. J., Moores, A., Mohrien, K. M., & Moores, L. K. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.05.025 · Cited by 24
The Prevention of Venous Thromboembolism in Surgical Patients
Hansrani, V., Khanbhai, M., & McCollum, C. N. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_100 · Cited by 27
Hamidi, M., Zeeshan, M., Sakran, J. V., Kulvatunyou, N., O’Keeffe, T., Northcutt, A., Zakaria, E. R., Tang, A. L., & Joseph, B. A. (2018) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2018.09.023 · Cited by 22
Therapeutic Potential of Oral Factor Xa Inhibitors
Hylek, E. M. (2010) · New England Journal of Medicine · doi:10.1056/nejme1012149 · Cited by 22
Gill, D., & Burgess, S. (2020) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.003061 · Cited by 21
Salakolusu, S., Sharma, G. V. R., Katari, N. K., Puppala, U., Kaliyapermal, M., Vijay, R., Doddipalla, R., & Geereddi, M. K. R. (2022) · Journal of Separation Science · doi:10.1002/jssc.202200466 · Cited by 21
Edoxaban: Pharmacological principles, Preclinical and early-phase Clinical Testing
Partida, R. A., & Giugliano, R. P. (2011) · Future Cardiology · doi:10.2217/fca.11.28 · Cited by 21
“5%), without an associated increase in bleeding events [39].”
BackgroundSecrétan, P.-H., Yayé, H. S., Aymes‐Chodur, C., Bernard, M., Solgadi, A., Amrani, F., Yagoubi, N., & Do, B. (2015) · RSC Advances · doi:10.1039/c5ra00171d · Cited by 25
Novel Oral Anticoagulants: A Review of New Agents
Wanat, M. A. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.07.2683 · Cited by 25
Use of novel oral anticoagulant agents in venous thromboembolism
Madan, S., Shah, S., Dale, P., Partovi, S., & Parikh, S. A. (2016) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2016.11.17 · Cited by 23
“In contrast to ADVANCE-1, ADVANCE-2 demonstrated increased efficacy with use of apixaban compared to enoxaparin.”
MethodInfluentialOral anticoagulants in the management of venous thromboembolism
Makaryus, J. N., Halperin, J. L., & Lau, J. F. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.73 · Cited by 28
Calderone, A., Stevens, W., Prior, D., Nandurkar, H. H., Gabbay, E., Proudman, S., Williams, T. J., Celermajer, D. S., Sahhar, J., Wong, P. K. K., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011028 · Cited by 21
“5 mg two times a day) may yield comparable efficacy to full-dose apixaban in certain clinical settings, such as thromboprophylaxis postarthroplasty or treatment of venous thromboembolism, with no increased risk of bleeding.(45) 46 52 Furthermore, in acute coronary syndromes, full-dose”
BackgroundCurrent Status of New Anticoagulants in the Management of Venous Thromboembolism
Montoya, R. C., & Gajra, A. (2012) · Advances in Hematology · doi:10.1155/2012/856341 · Cited by 22
“It was concluded that among patients undergoing hip replacement, thromboprophylaxis with apixaban, as compared with enoxaparin, was associated with lower rates of VTE, without increased bleeding [31].”
BackgroundMigliorini, F., Maffulli, N., Velaj, E., Bell, A., Kämmer, D., Eschweiler, J., & Hofmann, U. K. (2024) · European Journal of Orthopaedic Surgery & Traumatology · doi:10.1007/s00590-024-04071-w · Cited by 20
Deeks, E. D. (2012) · Drugs · doi:10.2165/11209020-000000000-00000 · Cited by 24
“%) apixaban or enoxaparin sodium recipients in either trial experienced symptomatic DVT (0.14% vs 0.07% in ADVANCE-2;[41] 0% vs 0.1% in ADVANCE-3[42]), fatal/nonfatal PE (0.21% vs 0.07%;[41] 0% vs 0.2%[42]) or all-cause death (0.07% in both groups;[41] 0.08% vs 0.04%[42]) [between-group statistical analyses were not r…”
InfluentialQuick reference guide to apixaban
Hurst, K. V., O'Callaghan, J. M., & Handa, A. I. (2017) · Vascular Health and Risk Management · doi:10.2147/vhrm.s121944 · Cited by 22
“09).(13,14) Although no direct RCTs have been performed for the use of apixaban in the prevention of VTE outside hip and knee surgery, the data shown throughout this article are considered to be strong enough evidence for the use of apixaban for this purpose.”
Merali, S. J., Byon, W., Myers, E., Li, X., Marchisin, D., & Murthy, B. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00348-2 · Cited by 20
Goh, E. L., Gurung, P., Ma, S., Pilpel, T., Dale, J. H., Kannan, A., & Anand, S. (2020) · Geriatric Orthopaedic Surgery & Rehabilitation · doi:10.1177/2151459319897520 · Cited by 27
“Furthermore, several studies have demonstrated that DOACs are associated with lower rates of VTE without increased risk of hemorrhage compared to conventional anticoagulants for lower limb orthopedic surgery.(10-15) However, there is limited evidence regarding the use of DOACs as VTE prophylaxis following surgery for…”
BackgroundResultMuscatelli, S. R., Zheng, H. T., Hughes, R. E., Cowen, M. E., & Hallstrom, B. R. (2021) · The Journal of Arthroplasty · doi:10.1016/j.arth.2021.01.025 · Cited by 21
Cada, D. J., Levien, T. L., & Baker, D. E. (2013) · Hospital Pharmacy · doi:10.1310/hpj4806-494 · Cited by 22
Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
Frost, C. E., Ly, V. T., & Merali, S. J. (2021) · Drugs in R&D · doi:10.1007/s40268-021-00359-y · Cited by 20
Implications of new anticoagulants in primary practice
Perez, A., Eraso, L. H., & Merli, G. J. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12023 · Cited by 21
Management of Bleeding Associated with Dabigatran and Rivaroxaban: A Survey of Current Practices
Kreuziger, L. B., & Reding, M. T. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.07.011 · Cited by 19
Inhibitors of propagation of coagulation: factors V and X
Toschi, V., & Lettino, M. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04001.x · Cited by 21
Brockbank, J., & Wolowacz, S. E. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0486-4 · Cited by 20
Metadata
- Authors
- Lassen, M. R., Gallus, A., Raskob, G. E., Pineo, G., Chen, D., & Ramirez, L. M.
- Affiliations
- University of Copenhagen (DK)
- South Australia Pathology (AU)
- University of Oklahoma Health Sciences Center (US)
- University of Calgary (CA)
- Bristol-Myers Squibb (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-12-23
- Volume
- 363
- Issue
- 26
- Pages
- 2487-2498
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2133686162
- Cited by
- 775
- References
- 35
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 32 · 2023: 18 · 2022: 25 · 2021: 33 · 2020: 34 · 2019: 39 · 2018: 41 · 2017: 39 · 2016: 62 · 2015: 66 · 2014: 67 · 2013: 121 · 2012: 102
- FWCI
- 76.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Murdoch University Research Portal (submittedVersion)
- Flinders Academic Commons (Flinders University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, enoxaparin, thromboprophylaxis, total hip arthroplasty, factor Xa inhibitors, low molecular weight heparin, deep vein thrombosis, pulmonary embolism, bleeding risk, venography, non-inferiority, postoperative thromboprophylaxis, oral anticoagulants, venous thromboembolism
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Anticoagulants, Double-Blind Method, Female, Hemorrhage, Humans, Injections, Subcutaneous, Male, Middle Aged, Postoperative Complications, Pyrazoles, Pyridones, Confidence Intervals, Treatment Outcome, Enoxaparin, Arthroplasty, Replacement, Hip, Venous Thromboembolism, Young Adult, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.